{"id":390054,"date":"2021-04-01T00:00:00","date_gmt":"2021-04-01T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0006-2020-biopharma-schizophrenia-disease-landscape-and-forecast-g7-2020\/"},"modified":"2026-03-31T10:43:35","modified_gmt":"2026-03-31T10:43:35","slug":"dlsfcg0006-2020-biopharma-schizophrenia-disease-landscape-and-forecast-g7-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0006-2020-biopharma-schizophrenia-disease-landscape-and-forecast-g7-2020\/","title":{"rendered":"Schizophrenia| Disease Landscape and Forecast | G7 | 2020"},"content":{"rendered":"<p>The schizophrenia therapy market is very crowded. Many of the antipsychotic therapies are generic, although newer oral atypical antipsychotics (e.g., Intra-Cellular Therapies\u2019 Caplyta) are also available. Competition is also intensifying among antipsychotic long-acting injectables (LAIs) as new therapies launch, offering largely incremental advantages over treatment mainstays. Indeed, late-phase emerging therapies\u2014including new oral atypical antipsychotics (Alkermes\u2019s ALKS 3831, Acadia Pharmaceuticals\u2019 pimavanserin), new LAIs (e.g., Janssen\u2019s paliperidone six-month depot, Teva\u2019s TV-46000), and others (Sunovion \/ Sumitomo Dainippon Pharma\u2019s SEP-363856, BioXcel\u2019s BXCL501)\u2014must be clearly differentiated from established therapies to gain a foothold in this market. The potential of early- to mid-phase therapies to treat the negative symptoms and cognitive impairment associated with schizophrenia (CIAS)\u2014symptom domains on which drug developers are increasingly focusing\u2014remains to be seen; few agents have promising results in mid-phase clinical studies (e.g., Boehringer Ingelheim\u2019s BI 425809 in CIAS).<\/p>\n<p><strong>Questions <\/strong><strong>Answered<\/strong><\/p>\n<ul>\n<li>What is the current size of the schizophrenia market in the G7 countries? What key events will influence the market over the next decade?<\/li>\n<li>What factors drive and constrain the use of LAIs of atypical antipsychotics? How is competition heating up in this segment?<\/li>\n<li>What are the biggest areas of unmet need? Which late-phase therapies have potential to fulfill these needs?<\/li>\n<li>What would key late-phase therapies need to demonstrate in order to compete effectively in this crowded market? How will these agents be placed in the schizophrenia treatment algorithm?<\/li>\n<\/ul>\n<p><strong>Product Description: <\/strong>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Geographies:<\/strong> United States, EU5, Japan.<\/p>\n<p><strong>Primary research: <\/strong>29 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other DRG research.<\/p>\n<p><strong>Epidemiology: <\/strong>Diagnosed prevalence of schizophrenia by country, segmented by positive symptoms and negative symptoms; drug-treated prevalence of schizophrenia by country.<\/p>\n<p><strong>Forecast:<\/strong> Ten-year, annualized, drug-level sales and patient share of key schizophrenia therapies through 2029, segmented by brands \/ generics.<\/p>\n<p><strong>Emerging therapies: <\/strong>Phase III \/ PR: 10\u00a0drugs. Coverage of select Phase II and Phase I products.<\/p>\n","protected":false},"template":"","class_list":["post-390054","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-schizophrenia","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390054\/revisions"}],"predecessor-version":[{"id":576422,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390054\/revisions\/576422"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}